Devgen SA
2.9 FTEThe score of Devgen shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -82 % Equity +15 % Total assets +15 % Headcount (avg FTE) -90 %
Accounts of the company itself (not consolidated). Consolidated group accounts are also filed: they are in the full file.
The full file covers 12 financial years; a free account shows 2. →Devgen's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Jul 2026
- Year ended 31 Dec 2024filed on 11 Jul 2025
- Year ended 31 Dec 2023filed on 09 Jul 2024
- Year ended 31 Dec 2022filed on 24 Oct 2023
- Year ended 31 Dec 2021filed on 24 Jul 2023
Devgen's financial analysis
- Solvency98.0%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Devgen
Devgen's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0461.432.562
- VAT number
- BE0461432562
- Peppol
- Registered · 0208:0461432562 · as of 24 Oct 2026
- Legal form
- SA
- Incorporated
- 11 Sep 1997
- Registered office
- 9052 Ghent
- Size
- Micro · 2.9 FTE
- Latest accounts
- 2025 · filed on 20 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Devgen (SA) has been based in Ghent since 1997, active in: research and experimental development on biotechnology. For 2025, it reports revenue of €1.13m, a net profit of €2.94m and equity of €128.3m. With 2.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 98.0%, above the median of its sector (61.7%).
Companies similar to Devgen
Companies in the same business, of comparable size and area, outside its group.
- AgomAb Therapeutics Technical testing and analysis Antwerp · balance sheet €251.3m
- Confo Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €37.8m
- MDxHealth Research and experimental development on natural sciences and engineering Herstal · balance sheet €159.3m
- iTeos Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet €46.3m
- The Oncidium Foundation Research and experimental development on natural sciences and engineering Auderghem · balance sheet €60.5m
- Ncardia Holding Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €108.4m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- Augustine Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €30.9m
Frequently asked questions about Devgen
What is the revenue of Devgen?
According to the 2025 annual accounts filed with the NBB, the revenue of Devgen amounts to 1,129,661 €.
What is the VAT number of Devgen?
In Belgium, the VAT number is the company number prefixed with BE: BE0461432562 for Devgen, if the company is VAT-registered. Its company number (CBE) is 0461.432.562.
Where is the registered office of Devgen?
According to the CBE register, the registered office of Devgen is in 9052 Ghent.
What is the equity of Devgen?
At the close of the 2025 financial year, the equity of Devgen amounts to 128,321,921 €, a solvency of 98.0% of total assets.
How many people work at Devgen?
2.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Devgen?
The register lists 4 active mandates at Devgen. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Devgen
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →